These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 26077113)

  • 1. Insulin dose adjustments with add-on glucagon-like peptide-1 receptor (GLP-1R) agonists in clinical practice.
    Artigas CF; Stokes V; Tan GD; Theodorakis MJ
    Expert Opin Pharmacother; 2015; 16(10):1417-21. PubMed ID: 26077113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association.
    Cariou B
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S28-6S35. PubMed ID: 26774017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
    Goldenberg RM; Berard L
    Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes.
    Lovshin JA
    Can J Diabetes; 2017 Oct; 41(5):524-535. PubMed ID: 28942790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
    Deacon CF; Mannucci E; Ahrén B
    Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of GLP-1 receptor agonists for type 2 diabetes treatment intensification after basal insulin failure.
    Joubert M; Reznik Y
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S34-2S38. PubMed ID: 28431670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of insulin-GLP-1 receptor agonists combination in type 2 diabetes mellitus: a systematic review.
    Cimmaruta D; Maiorino MI; Scavone C; Sportiello L; Rossi F; Giugliano D; Esposito K; Capuano A
    Expert Opin Drug Saf; 2016 Dec; 15(sup2):77-83. PubMed ID: 27875915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety and benefits of GLP-1 receptor agonists.
    Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
    Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of new GLP-1 receptor agonists for type 2 diabetes.
    Tomlinson B; Hu M; Zhang Y; Chan P; Liu ZM
    Expert Opin Investig Drugs; 2016; 25(2):145-58. PubMed ID: 26587691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GLP-1 as a target for therapeutic intervention.
    Rajeev SP; Wilding J
    Curr Opin Pharmacol; 2016 Dec; 31():44-49. PubMed ID: 27591964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
    Morales J
    Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis.
    Geloneze B; de Lima-Júnior JC; Velloso LA
    Drugs; 2017 Apr; 77(5):493-503. PubMed ID: 28233273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding Rapid-Acting Insulin or GLP-1 Receptor Agonist to Basal Insulin: Outcomes in a Community Setting.
    Dalal MR; Xie L; Baser O; DiGenio A
    Endocr Pract; 2015 Jan; 21(1):68-76. PubMed ID: 25148821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial injectable therapy in type 2 diabetes: Key considerations when choosing between glucagon-like peptide 1 receptor agonists and insulin.
    Alexopoulos AS; Buse JB
    Metabolism; 2019 Sep; 98():104-111. PubMed ID: 31255662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Not Available].
    Leiter LA; Nauck MA
    Exp Clin Endocrinol Diabetes; 2017 Jul; 125(7):419-435. PubMed ID: 28724168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies of insulin vs glucagon-like peptide-1 receptor agonists in patients initiating injectable therapy.
    Dejgaard TF; Madsbad S
    Diabetes Obes Metab; 2017 Feb; 19(2):153-155. PubMed ID: 27735120
    [No Abstract]   [Full Text] [Related]  

  • 19. Individualized, patient-centered use of lixisenatide for the treatment of type 2 diabetes mellitus.
    Hanefeld M; Raccah D; Monnier L
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):311-321. PubMed ID: 27776453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injectable combination therapies for the management of diabetes: an Indian perspective.
    Dutta D; Khandelwal D; Kalra S
    Expert Opin Drug Metab Toxicol; 2020 Mar; 16(3):209-216. PubMed ID: 32098522
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.